Literature DB >> 29025911

Treat or palliate: outcomes of very elderly myeloma patients.

Fotios Panitsas1, Jaimal Kothari2, Grant Vallance2, Faouzi Djebbari2, Lisa Ferguson2, Manuela Sultanova2, Karthik Ramasamy2,3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29025911      PMCID： PMC5777212          DOI： 10.3324/haematol.2017.173617

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

Authors:  Antonio Palumbo; Sara Bringhen; Maria-Victoria Mateos; Alessandra Larocca; Thierry Facon; Shaji K Kumar; Massimo Offidani; Philip McCarthy; Andrea Evangelista; Sagar Lonial; Sonja Zweegman; Pellegrino Musto; Evangelos Terpos; Andrew Belch; Roman Hajek; Heinz Ludwig; A Keith Stewart; Philippe Moreau; Kenneth Anderson; Hermann Einsele; Brian G M Durie; Meletios A Dimopoulos; Ola Landgren; Jesus F San Miguel; Paul Richardson; Pieter Sonneveld; S Vincent Rajkumar
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

2.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

3.  Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

Authors:  Ruben Niesvizky; Ian W Flinn; Robert Rifkin; Nashat Gabrail; Veena Charu; Billy Clowney; James Essell; Yousuf Gaffar; Thomas Warr; Rachel Neuwirth; Yanyan Zhu; Jennifer Elliott; Dixie-Lee Esseltine; Liviu Niculescu; James Reeves
Journal:  J Clin Oncol       Date:  2015-06-08       Impact factor: 44.544

4.  Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.

Authors:  Meletios A Dimopoulos; Efstathios Kastritis; Sossana Delimpasi; Eirini Katodritou; Eleftheria Hatzimichael; Marie-Christine Kyrtsonis; Panagiotis Repousis; Maria Tsirogianni; Zafiris Kartasis; Agapi Parcharidou; Michalis Michael; Eurydiki Michalis; Constantinos Tsatalas; Ekaterini Stefanoudaki; Eudoxia Hatjiharissi; Dimitra Gika; Argiris Symeonidis; Evangelos Terpos; Konstantinos Zervas
Journal:  Eur J Haematol       Date:  2012-07       Impact factor: 2.997

5.  Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

6.  Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: comparison with patients in different age groups in the era of novel agents.

Authors:  Kosei Matsue; Yuya Matsue; Manabu Fujisawa; Kota Fukumoto; Yasuhito Suehara; Hiroki Sugihara; Masami Takeuchi
Journal:  Leuk Lymphoma       Date:  2015-07-07

7.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

9.  Multiple myeloma in the very old: an IASIA conference report.

Authors:  Sascha A Tuchman; Gary R Shapiro; William B Ershler; Ashraf Badros; Harvey J Cohen; Angela Dispenzieri; Irene Q Flores; Bindu Kanapuru; Donald Jurivich; Dan L Longo; Ali Nourbakhsh; Antonio Palumbo; Jeremy Walston; Jerome W Yates
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

Review 10.  Multiple myeloma in the very elderly patient: challenges and solutions.

Authors:  John Willan; Toby A Eyre; Faye Sharpley; Caroline Watson; Andrew J King; Karthik Ramasamy
Journal:  Clin Interv Aging       Date:  2016-04-15       Impact factor: 4.458
View more
  3 in total

Review 1.  How I treat elderly patients with plasma cell dyscrasias.

Authors:  Maria Gavriatopoulou; Despoina Fotiou; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Evangelos Terpos; Meletios Athanasios Dimopoulos
Journal:  Aging (Albany NY)       Date:  2018-12-18       Impact factor: 5.682

2.  Multiple Myeloma in Patients over 80: A Real World Retrospective Study of First Line Conservative Approach with Bortezomib Dexamethasone Doublet Therapy and Mini-Review of Literature.

Authors:  Laurence Huynh; Rudy Birsen; Lucie Mora; Anne-Laure Couderc; Nathalie Mitha; Anaïs Farcet; Amale Chebib; Pascal Chaibi
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

3.  Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry.

Authors:  Hans C Lee; Sikander Ailawadhi; Cristina J Gasparetto; Sundar Jagannath; Robert M Rifkin; Brian G M Durie; Mohit Narang; Howard R Terebelo; Kathleen Toomey; James W Hardin; Lynne Wagner; James L Omel; Mazaher Dhalla; Liang Liu; Prashant Joshi; Rafat Abonour
Journal:  Blood Cancer J       Date:  2021-07-23       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.